相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Continuous endoglin (CD105) overexpression disrupts angiogenesis and facilitates tumor cell metastasis
Claudia Ollauri-Ibanez et al.
ANGIOGENESIS (2020)
Imatinib revives the therapeutic potential of metformin on ewing sarcoma by attenuating tumor hypoxic response and inhibiting convergent signaling pathways
Xiang Nan et al.
CANCER LETTERS (2020)
Transforming growth factor-β signaling, a potential mechanism associated with diabetes mellitus and pancreatic cancer?
Xingyuan Ma et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2020)
Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial
Antoine Italiano et al.
LANCET ONCOLOGY (2020)
Bevacizumab for NF2-associated vestibular schwannomas of childhood and adolescence
Samuele Renzi et al.
PEDIATRIC BLOOD & CANCER (2020)
Role of Angiopoietins in Development of Cancer and Neoplasia Associated with Viral Infection
Xiaolan Yu et al.
CELLS (2020)
A phase 2 study of valproic acid and radiation, followed by maintenance valproic acid and bevacizumab in children with newly diagnosed diffuse intrinsic pontine glioma or high-grade glioma
Jack Meng-Fen Su et al.
PEDIATRIC BLOOD & CANCER (2020)
Cabozantinib for relapsed neuroblastoma: Single institution case series
Michael P. Perisa et al.
PEDIATRIC BLOOD & CANCER (2020)
Recent advances in the molecular mechanism of thalidomide teratogenicity
Shaobing Gao et al.
BIOMEDICINE & PHARMACOTHERAPY (2020)
Phase I expansion cohort to evaluate the combination of bevacizumab, sorafenib and low-dose cyclophosphamide in children and young adults with refractory or recurrent solid tumours
Sara M. Federico et al.
EUROPEAN JOURNAL OF CANCER (2020)
Platelet-Specific PDGFB Ablation Impairs Tumor Vessel Integrity and Promotes Metastasis
Yanyu Zhang et al.
CANCER RESEARCH (2020)
Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook
Josep Garcia et al.
CANCER TREATMENT REVIEWS (2020)
Targeting the Tumor Microenvironment in Neuroblastoma: Recent Advances and Future Directions
Shweta Joshi
CANCERS (2020)
A Chart Review on the Feasibility and Safety of the Vincristine Irinotecan Pazopanib (VIPaz) Association in Children and Adolescents With Resistant or Relapsed Sarcomas
Ida Russo et al.
FRONTIERS IN ONCOLOGY (2020)
Pathological response in children and adults with large unresected intermediate-grade or high-grade soft tissue sarcoma receiving preoperative chemoradiotherapy with or without pazopanib (ARST1321): a multicentre, randomised, open-label, phase 2 trial
Aaron R. Weiss et al.
LANCET ONCOLOGY (2020)
Therapeutic Angiogenesis Using HGF Plasmid
Fumihiro Sanada et al.
ANNALS OF VASCULAR DISEASES (2020)
Anaplastic pleomorphic xanthoastrocytoma with leptomeningeal dissemination responsive to BRAF inhibition and bevacizumab
Alissa A. Thomas et al.
PEDIATRIC BLOOD & CANCER (2019)
Anti-CD105 Antibody Eliminates Tumor Microenvironment Cells and Enhances Anti-GD2 Antibody Immunotherapy of Neuroblastoma with Activated Natural Killer Cells
Hong-Wei Wu et al.
CLINICAL CANCER RESEARCH (2019)
Surgery, Octreotide, Temozolomide, Bevacizumab, Radiotherapy, and Pegvisomant Treatment of an AIP Mutation-Positive Child
Pinaki Dutta et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2019)
Cancer drugs approved for use in children: Impact of legislative initiatives and future opportunities
Amy Barone et al.
PEDIATRIC BLOOD & CANCER (2019)
Role of Angiopoietin-2 in Vascular Physiology and Pathophysiology
Racheal G. Akwii et al.
CELLS (2019)
New Insights about the Wnt/β-Catenin Signaling Pathway in Primary Bone Tumors and Their Microenvironment: A Promising Target to Develop Therapeutic Strategies?
Geoffroy Danieau et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
The global burden of childhood and adolescent cancer in 2017: an analysis of the Global Burden of Disease Study 2017
Lisa M. Force et al.
LANCET ONCOLOGY (2019)
Are Integrins Still Practicable Targets for Anti-Cancer Therapy?
Begona Alday-Parejo et al.
CANCERS (2019)
Fibroblast Growth Factor Receptor Signaling in Skin Cancers
Malgorzata Czyz
CELLS (2019)
Anti-VEGFR2 therapy delays growth of preclinical pediatric tumor models and enhances anti-tumor activity of chemotherapy
Caitlin D. Lowery et al.
Oncotarget (2019)
Tumor endothelial cells as a potential target of metronomic chemotherapy
Ji Yoon Kim et al.
ARCHIVES OF PHARMACAL RESEARCH (2019)
Role of Focal Adhesion Kinase in Small-Cell Lung Cancer and Its Potential as a Therapeutic Target
Frank Aboubakar Nana et al.
CANCERS (2019)
Compare and contrast: pediatric cancer versus adult malignancies
Patricia Kattner et al.
CANCER AND METASTASIS REVIEWS (2019)
Brain Metastases and Place of Antiangiogenic Therapies in Alveolar Soft Part Sarcoma: A Retrospective Analysis of the French Sarcoma Group
Gabriel G. Malouf et al.
ONCOLOGIST (2019)
Prolonged response to sorafenib in a patient with refractory metastatic osteosarcoma and a somatic PDGFRA D846V mutation
Amy E. Armstrong et al.
PEDIATRIC BLOOD & CANCER (2019)
Angiopoietin 2 signal complexity in cardiovascular disease and cancer
Giuseppina Nicolini et al.
LIFE SCIENCES (2019)
Use of bevacizumab as a single agent or in adjunct with traditional chemotherapy regimens in children with unresectable or progressive low-grade glioma
Nataliya Zhukova et al.
CANCER MEDICINE (2019)
Recent progress in pediatric soft tissue sarcoma therapy
Timothy B. Lautz et al.
SEMINARS IN PEDIATRIC SURGERY (2019)
Pazopanib maintenance therapy after tandem high-dose chemotherapy for disseminated Ewing sarcoma
Akihiro Tamura et al.
INTERNATIONAL CANCER CONFERENCE JOURNAL (2019)
FAK inhibitors in Cancer, a patent review
Peng-Cheng Lv et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2018)
Bevacizumab-associated Bowel Microperforation in a Patient With Neuroblastoma
Rachel Glincher et al.
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY (2018)
Clinical Activity of Pazopanib in Patients with Advanced Desmoplastic Small Round Cell Tumor
Brian A. Menegaz et al.
ONCOLOGIST (2018)
Bevacizumab-mediated tumor vasculature remodelling improves tumor infiltration and antitumor efficacy of GD2-CAR T cells in a human neuroblastoma preclinical model
Paola Bocca et al.
ONCOIMMUNOLOGY (2018)
Phase II, Open-Label, Randomized, Multicenter Trial (HERBY) of Bevacizumab in Pediatric Patients With Newly Diagnosed High-Grade Glioma
Jacques Grill et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Vincristine, Irinotecan, and Bevacizumab in Relapsed Wilms Tumor With Diffuse Anaplasia
Amalia Schiavetti et al.
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY (2018)
The PDGF/PDGFR pathway as a drug target
Natalia Papadopoulos et al.
MOLECULAR ASPECTS OF MEDICINE (2018)
Identification of FDA-Approved Oncology Drugs with Selective Potency in High-Risk Childhood Ependymoma
Andrew M. Donson et al.
MOLECULAR CANCER THERAPEUTICS (2018)
A High-Content Screening of Anticancer Compounds Suggests the Multiple Tyrosine Kinase Inhibitor Ponatinib for Repurposing in Neuroblastoma Therapy
Viktoryia Sidarovich et al.
MOLECULAR CANCER THERAPEUTICS (2018)
The landscape of genomic alterations across childhood cancers
Susanne N. Groebner et al.
NATURE (2018)
Single-agent bevacizumab in the treatment of recurrent or refractory pediatric low-grade glioma: A single institutional experience
Hamza S. Gorsi et al.
PEDIATRIC BLOOD & CANCER (2018)
Alveolar soft part sarcoma in children and young adults: A report of 69 cases
Ricardo J. Flores et al.
PEDIATRIC BLOOD & CANCER (2018)
A phase 1 study of cabozantinib in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: Trial ADVL1211, a report from the Children's Oncology Group
Meredith K. Chuk et al.
PEDIATRIC BLOOD & CANCER (2018)
Hypoxia-Targeting Drug Evofosfamide (TH-302) Enhances Sunitinib Activity in Neuroblastoma Xenograft Models
Sushil Kumar et al.
TRANSLATIONAL ONCOLOGY (2018)
Anti-Angiogenics: Current Situation and Future Perspectives
Katja Zirlik et al.
ONCOLOGY RESEARCH AND TREATMENT (2018)
Updated clinical and biological information from the two-stage phase II study of imatinib mesylate in subjects with relapsed/refractory neuroblastoma
Fabio Morandi et al.
ONCOIMMUNOLOGY (2018)
The Dual Role of Bone Morphogenetic Proteins in Cancer
Duc-Hiep Bach et al.
MOLECULAR THERAPY-ONCOLYTICS (2018)
Recent developments and advances of FGFR as a potential target in cancer
Wen-Jun Xue et al.
FUTURE MEDICINAL CHEMISTRY (2018)
Sorafenib in patients with progressed and refractory bone tumors
Anna Raciborska et al.
MEDICAL ONCOLOGY (2018)
Pediatric Case of Li-Fraumeni Syndrome Complicated with Supratentorial Anaplastic Ependymoma
Tomohiro Hosoya et al.
WORLD NEUROSURGERY (2018)
A study of axitinib, a VEGF receptor tyrosine kinase inhibitor, in children and adolescents with recurrent or refractory solid tumors: A Children's Oncology Group phase 1 and pilot consortium trial (ADVL1315)
James Geller et al.
CANCER (2018)
The Major Causes of Death in Children and Adolescents in the United States
Rebecca M. Cunningham et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Vascular stenosis in a child with visual pathway glioma treated with bevacizumab: a case report and review of literature
Chiara Pilotto et al.
CHILDS NERVOUS SYSTEM (2018)
The role of endoglin in post-ischemic revascularization
Elena Nunez-Gomez et al.
ANGIOGENESIS (2017)
Docetaxel, bevacizumab, and gemcitabine for very high risk sarcomas in adolescents and young adults: A single-center experience
Christopher Kuo et al.
PEDIATRIC BLOOD & CANCER (2017)
Open-label, multicentre, randomised, phase II study of the EpSSG and the ITCC evaluating the addition of bevacizumab to chemotherapy in childhood and adolescent patients with metastatic soft tissue sarcoma (the BERNIE study)
Julia C. Chisholm et al.
EUROPEAN JOURNAL OF CANCER (2017)
Endoglin-based biological therapy in the treatment of angiogenesis-dependent pathologies
Claudia Ollauri-Ibanez et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2017)
Imatinib mesylate in desmoplastic small round cell tumors
Rita De Sanctis et al.
FUTURE ONCOLOGY (2017)
A phase II trial evaluating the feasibility of adding bevacizumab to standard osteosarcoma therapy
Fariba Navid et al.
INTERNATIONAL JOURNAL OF CANCER (2017)
Dramatic Reduction in Tumor Size During 5 Months of Pazopanib Therapy in Combination With Ifosfamide, Carboplatin, and Etoposide in an Early Infant With Progressive Soft Tissue Sarcoma
Tatsuo Watanabe et al.
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY (2017)
The Significant Effects of Pazopanib on Multiple Pulmonary Metastatic Lesions of Alveolar Soft Part Sarcoma: A Case Report
Yasutomo Funakoshi et al.
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY (2017)
Bevacizumab Therapy for Pilomyxoid Astrocytoma
Ryan D. Metts et al.
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY (2017)
The role of angiogenesis in Group 3 medulloblastoma pathogenesis and survival
Eric M. Thompson et al.
NEURO-ONCOLOGY (2017)
High expression levels of Cyr61 and VEGF are associated with poor prognosis in osteosarcoma
Yanming Liu et al.
PATHOLOGY RESEARCH AND PRACTICE (2017)
Combination of bevacizumab, irinotecan, and temozolomide for refractory or relapsed neuroblastoma: Results of a phase II study
Shakeel Modak et al.
PEDIATRIC BLOOD & CANCER (2017)
Pazopanib for second recurrence of osteosarcoma in pediatric patients
Katsutsugu Umeda et al.
PEDIATRICS INTERNATIONAL (2017)
Response to pazopanib in two pediatric patients with pretreated relapsing synovial sarcoma
Michela Casanova et al.
TUMORI JOURNAL (2017)
Molecular Guided Therapy Provides Sustained Clinical Response in Refractory Choroid Plexus Carcinoma
Albert Cornelius et al.
FRONTIERS IN PHARMACOLOGY (2017)
Response to pazopanib in two pediatric patients with pretreated relapsing synovial sarcoma
Michela Casanova et al.
TUMORI JOURNAL (2017)
Pediatric Phase I Trial and Pharmacokinetic Study of Trebananib in Relapsed Solid Tumors, Including Primary Tumors of the Central Nervous System ADVL1115: A Children's Oncology Group Phase I Consortium Report
Sarah E. S. Leary et al.
CLINICAL CANCER RESEARCH (2017)
Tumor angiogenesis and vascular normalization: alternative therapeutic targets
Claire Viallard et al.
ANGIOGENESIS (2017)
Comprehensive Analysis of Hypermutation in Human Cancer
Brittany B. Campbell et al.
CELL (2017)
Efficient VEGF targeting delivery of DOX using Bevacizumab conjugated SiO2@LDH for anti-neuroblastoma therapy
Rongrong Zhu et al.
ACTA BIOMATERIALIA (2017)
Prognostic impact of blood and urinary angiogenic factor levels at diagnosis and during treatment in patients with osteosarcoma: a prospective study
Marie-Dominique Tabone et al.
BMC CANCER (2017)
Pediatric Cancer Predisposition and Surveillance: An Overview, and a Tribute to Alfred G. Knudson Jr
Garrett M. Brodeur et al.
CLINICAL CANCER RESEARCH (2017)
Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy?
Rakesh R. Ramjiawan et al.
ANGIOGENESIS (2017)
Advances and challenges in targeting FGFR signalling in cancer
Irina S. Babina et al.
NATURE REVIEWS CANCER (2017)
Endothelial cell-derived angiopoietin-2 is a therapeutic target in treatment-naive and bevacizumab-resistant glioblastoma
Alexander Scholz et al.
EMBO MOLECULAR MEDICINE (2016)
A pilot study of bevacizumab-based therapy in patients with newly diagnosed high-grade gliomas and diffuse intrinsic pontine gliomas
Trent R. Hummel et al.
JOURNAL OF NEURO-ONCOLOGY (2016)
Preoperative Treatment With Pazopanib in a Case of Chemotherapy-Resistant Infantile Fibrosarcoma
Ryu Yanagisawa et al.
PEDIATRIC BLOOD & CANCER (2016)
Pediatric phase I trial of oral sorafenib and topotecan in refractory or recurrent pediatric solid malignancies
Damon R. Reed et al.
CANCER MEDICINE (2016)
Targeting tumour vasculature by inhibiting activin receptor-like kinase (ALK)1 function
Amaya Garcia de Vinuesa et al.
BIOCHEMICAL SOCIETY TRANSACTIONS (2016)
A Phase I, First-in-Human Study of AMG 780, an Angiopoietin-1 and-2 Inhibitor, in Patients with Advanced Solid Tumors
Afshin Dowlati et al.
CLINICAL CANCER RESEARCH (2016)
The Childhood Solid Tumor Network: A new resource for the developmental biology and oncology research communities
Elizabeth Stewart et al.
DEVELOPMENTAL BIOLOGY (2016)
Recurrent MET fusion genes represent a drug target in pediatric glioblastoma
Sebastian Bender et al.
NATURE MEDICINE (2016)
Endoglin targeting inhibits tumor angiogenesis and metastatic spread in breast cancer
M. Paauwe et al.
ONCOGENE (2016)
Severe Radiation Necrosis Successfully Treated With Bevacizumab in an Infant with Low-Grade Glioma and Tumor-Associated Intractable Trigeminal Neuralgia
Natasha Pillay Smiley et al.
PEDIATRIC BLOOD & CANCER (2016)
Sorafenib treatment in children with relapsed and refractory neuroblastoma: an experience of four cases
Keiko Okada et al.
CANCER MEDICINE (2016)
Phase II evaluation of sunitinib in the treatment of recurrent or refractory high-grade glioma or ependymoma in children: a children's Oncology Group Study ACNS1021
Cynthia Wetmore et al.
CANCER MEDICINE (2016)
PlGF and VEGF-A Regulate Growth of High-Risk MYCN-Single Copy Neuroblastoma Xenografts via Different Mechanisms
Karin Zins et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2016)
Proof of principle for bevacizumab activity in desmoid-type fibromatosis
Viktor Gruenwald et al.
CLINICAL SARCOMA RESEARCH (2016)
Targeted antiangiogenic agents in combination with cytotoxic chemotherapy in preclinical and clinical studies in sarcoma
Kieuhoa T. Vo et al.
CLINICAL SARCOMA RESEARCH (2016)
Off-label use of targeted therapies in osteosarcomas: data from the French registry OUTC'S (Observatoire de l'Utilisation des Therapies Ciblees dans les Sarcomes)
Mathilde Penel-Page et al.
BMC CANCER (2015)
Sensitivity of neuroblastoma to the novel kinase inhibitor cabozantinib is mediated by ERK inhibition
Linna Zhang et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2015)
An open-label, two-stage, phase II study of bevacizumab and lapatinib in children with recurrent or refractory ependymoma: a collaborative ependymoma research network study (CERN)
Mariko DeWire et al.
JOURNAL OF NEURO-ONCOLOGY (2015)
Decreased tumor apparent diffusion coefficient correlates with objective response of pediatric low-grade glioma to bevacizumab
Christopher H. Hsu et al.
JOURNAL OF NEURO-ONCOLOGY (2015)
Confirmation of Bevacizumab Activity, and Maintenance of Efficacy in Retreatment After Subsequent Relapse, in Pediatric Low-grade Glioma
Manas Kalra et al.
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY (2015)
Pneumothorax as a complication of combination antiangiogenic therapy in children and young adults with refractory/recurrent solid tumors
Rodrigo B. Interiano et al.
JOURNAL OF PEDIATRIC SURGERY (2015)
Endoglin (CD 105) as a Potential Prognostic Factor in Neuroblastoma
Stanko Cavar et al.
PEDIATRIC BLOOD & CANCER (2015)
Phase 2 trial of sorafenib in children and young adults with refractory solid tumors: A report from the Children's Oncology Group
AeRang Kim et al.
PEDIATRIC BLOOD & CANCER (2015)
Long-term efficacy of bevacizumab and irinotecan in recurrent pediatric glioblastoma
Katsutsugu Umeda et al.
PEDIATRICS INTERNATIONAL (2015)
Personalized comprehensive molecular profiling of high risk osteosarcoma: Implications and limitations for precision medicine
Vivek Subbiah et al.
ONCOTARGET (2015)
Preclinical evaluation of dasatinib alone and in combination with cabozantinib for the treatment of diffuse intrinsic pontine glioma
Nathalene Truffaux et al.
NEURO-ONCOLOGY (2015)
Growth Plate Abnormalities in Pediatric Cancer Patients Undergoing Phase 1 Anti-Angiogenic Therapy: A Report From the Children's Oncology Group Phase I Consortium
Stephan D. Voss et al.
PEDIATRIC BLOOD & CANCER (2015)
Cerebral Radiation Necrosis in Pediatric Patients
S. Reed Plimpton et al.
PEDIATRIC HEMATOLOGY AND ONCOLOGY (2015)
Expression of Ki-67, p53 and VEGF in Pediatric Neuroblastoma
Elmira Gheytanchi et al.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION (2014)
Apurinic/apyrimidinic endonuclease 1 induced upregulation of fibroblast growth factor 2 and its receptor 3 induces angiogenesis in human osteosarcoma cells
Tao Ren et al.
CANCER SCIENCE (2014)
Anti-angiogenic therapy in pediatric brain tumors: An effective strategy?
Mariska Sie et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2014)
Extended Progression-Free Survival in Two Patients With Alveolar Soft Part Sarcoma Exposed to Tivantinib
John M. Goldberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Peripheral medulloepithelioma: a rare tumor with a potential target therapy
Maria Debora De Pasquale et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2014)
Trilateral retinoblastoma: a systematic review and meta-analysis
Marcus C. de Jong et al.
LANCET ONCOLOGY (2014)
Efficacy of bevacizumab plus irinotecan in children with recurrent Low-grade gliomas-a Pediatric Brain Tumor Consortium study
Sridharan Gururangan et al.
NEURO-ONCOLOGY (2014)
Phase II study of sorafenib in children with recurrent or progressive low-grade astrocytomas
Matthias A. Karajannis et al.
NEURO-ONCOLOGY (2014)
Treatment of Multiply Relapsed Wilms Tumor With Vincristine, Irinotecan, Temozolomide and Bevacizumab
Rajkumar Venkatramani et al.
PEDIATRIC BLOOD & CANCER (2014)
Malignant Transformation of Infantile Hemangioma to Angiosarcoma: Response to Chemotherapy With Bevacizumab
Michael R. Jeng et al.
PEDIATRIC BLOOD & CANCER (2014)
Sunitinib Suppress Neuroblastoma Growth through Degradation of MYCN and Inhibition of Angiogenesis
Raul Calero et al.
PLOS ONE (2014)
In comparative analysis of Multi-Kinase Inhibitors for Targeted Medulloblastoma Therapy Pazopanib exhibits promising in vitro and in vivo efficacy
Rogerio B. Craveiro et al.
ONCOTARGET (2014)
Marked Recovery of Vision in Children With Optic Pathway Gliomas Treated With Bevacizumab
Robert A. Avery et al.
JAMA OPHTHALMOLOGY (2014)
Dermatofibrosarcoma Protuberans in Pediatric Patients: A Report of 17 Cases
Claudia J. Posso-De Los Rios et al.
JOURNAL OF CUTANEOUS MEDICINE AND SURGERY (2014)
Two-stage phase II study of imatinib mesylate in subjects with refractory or relapsing neuroblastoma
L. Calafiore et al.
ANNALS OF ONCOLOGY (2013)
Anti-angiogenesis in neuroblastoma
Domenico Ribatti
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2013)
Activin receptor-like kinase 1 as a target for anti-angiogenesis therapy
Lukas J. A. C. Hawinkels et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2013)
Phase I Study of Bevacizumab Plus Irinotecan in Pediatric Patients with Recurrent/Refractory Solid Tumors
Keiko Okada et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2013)
Recurrent Ascites in a Patient With Low-grade Astrocytoma and Ventriculo-Peritoneal Shunt Treated With the Multikinase Inhibitor Sorafenib
Geneviève Legault et al.
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY (2013)
HIF-1α activation mediates resistance to anti-angiogenic therapy in neuroblastoma xenografts
Joseph Hartwich et al.
JOURNAL OF PEDIATRIC SURGERY (2013)
Long-term efficacy and toxicity of bevacizumab-based therapy in children with recurrent low-grade gliomas
Eugene I. Hwang et al.
PEDIATRIC BLOOD & CANCER (2013)
Pilot study of vincristine, oral irinotecan, and temozolomide (VOIT regimen) combined with bevacizumab in pediatric patients with recurrent solid tumors or brain tumors
Lars Wagner et al.
PEDIATRIC BLOOD & CANCER (2013)
Paediatric and Adolescent Alveolar Soft Part Sarcoma: A Joint Series From European Cooperative Groups
D. Orbach et al.
PEDIATRIC BLOOD & CANCER (2013)
A Phase I Study of Vincristine, Irinotecan, Temozolomide and Bevacizumab (Vitb) in Pediatric Patients with Relapsed Solid Tumors
Rajkumar Venkatramani et al.
PLOS ONE (2013)
Incidence and clinical course of radionecrosis in children with brain tumors A 20-year longitudinal observational study
V. Strenger et al.
STRAHLENTHERAPIE UND ONKOLOGIE (2013)
Tumor Dynamics in Response to Antiangiogenic Therapy with Oral Metronomic Topotecan and Pazopanib in Neuroblastoma Xenografts
Sushil Kumar et al.
TRANSLATIONAL ONCOLOGY (2013)
Opportunities and challenges for successful use of bevacizumab in pediatrics
Amy Barone et al.
FRONTIERS IN ONCOLOGY (2013)
Sorafenib inhibits endogenous and IL-6/S1P induced JAK2-STAT3 signaling in human neuroblastoma, associated with growth suppression and apoptosis
Fan Yang et al.
CANCER BIOLOGY & THERAPY (2012)
A Phase I Trial and Pharmacokinetic Study of Aflibercept (VEGF Trap) in Children with Refractory Solid Tumors: A Children's Oncology Group Phase I Consortium Report
Julia Glade Bender et al.
CLINICAL CANCER RESEARCH (2012)
Childhood adrenocortical carcinoma as a sentinel cancer for detecting families with germline TP53 mutations
S. S. Choong et al.
CLINICAL GENETICS (2012)
Novel targets for VEGF-independent anti-angiogenic drugs
Marco Petrillo et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2012)
Angiogenin up-regulation correlates with adverse clinicopathological and biological factors, increased microvascular density and poor patient outcome in neuroblastomas
Josiah V. Dungwa et al.
HISTOPATHOLOGY (2012)
Expression of Vascular Endothelial Growth Factor correlates with the advance of clinical osteosarcoma
John Lammli et al.
INTERNATIONAL ORTHOPAEDICS (2012)
Gemcitabine, Docetaxel, and Bevacizumab in Relapsed and Refractory Pediatric Sarcomas
Pooja Hingorani et al.
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY (2012)
Prolonged Survival After Treatment of Diffuse Intrinsic Pontine Glioma with Radiation, Temozolamide, and Bevacizumab
Dolly G. Aguilera et al.
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY (2012)
Lack of efficacy of bevacizumab plus irinotecan in cases of pediatric recurrent ependymoma - a Pediatric Brain Tumor Consortium study
Sridharan Gururangan et al.
NEURO-ONCOLOGY (2012)
In vitro anti-neuroblastoma activity of saquinavir and its association with imatinib
Fabio Timeus et al.
ONCOLOGY REPORTS (2012)
Sorafenib inhibits neuroblastoma cell proliferation and signaling, blocks angiogenesis, and impairs tumor growth
Nisha C. Kakodkar et al.
PEDIATRIC BLOOD & CANCER (2012)
Alveolar soft part sarcoma in childhood: Is Sunitinib-Sutent® treatment an effective approach?
Marjorie Hilbert et al.
PEDIATRIC BLOOD & CANCER (2012)
Antiangiogenic metronomic therapy for children with recurrent embryonal brain tumors
Andreas Peyrl et al.
PEDIATRIC BLOOD & CANCER (2012)
Bevacizumab and irinotecan in children with recurrent or refractory brain tumors: Toxicity and efficacy trends
Marie-Laure Couec et al.
PEDIATRIC BLOOD & CANCER (2012)
Targeted Therapy in Bone and Soft Tissue Sarcoma in Children and Adolescents
Patrick A. Thompson et al.
CURRENT ONCOLOGY REPORTS (2012)
Effect of MDM2 and vascular endothelial growth factor inhibition on tumor angiogenesis and metastasis in neuroblastoma
Danielle M. Patterson et al.
ANGIOGENESIS (2011)
ALK1 as an emerging target for antiangiogenic therapy of cancer
Sara I. Cunha et al.
BLOOD (2011)
Metronomic Oral Topotecan with Pazopanib Is an Active Antiangiogenic Regimen in Mouse Models of Aggressive Pediatric Solid Tumor
Sushil Kumar et al.
CLINICAL CANCER RESEARCH (2011)
The selective VEGFR1-3 inhibitor axitinib (AG-013736) shows antitumor activity in human neuroblastoma xenografts
Jochen Roessler et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
Treatment of children with recurrent high grade gliomas with a bevacizumab containing regimen
Chintan Parekh et al.
JOURNAL OF NEURO-ONCOLOGY (2011)
Sunitinib induces PTEN expression and inhibits PDGFR signaling and migration of medulloblastoma cells
Thamara J. Abouantoun et al.
JOURNAL OF NEURO-ONCOLOGY (2011)
Antiangiogenic Treatment as a Pre-Operative Management of Alveolar Soft-Part Sarcoma
Nuria Conde et al.
PEDIATRIC BLOOD & CANCER (2011)
Angiogenesis and Vascular Targeting in Ewing Sarcoma A Review of Preclinical and Clinical Data
Steven G. DuBois et al.
CANCER (2010)
Platelet-Derived Growth Factor Receptor β Inhibition Increases Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) Sensitivity Imatinib and TRAIL Dual Therapy
Yongxin Wang et al.
CANCER (2010)
Preclinical Evaluation of Radiation and Perifosine in a Genetically and Histologically Accurate Model of Brainstem Glioma
Oren J. Becher et al.
CANCER RESEARCH (2010)
Targets for cancer therapy in childhood sarcomas
Marco Wachtel et al.
CANCER TREATMENT REVIEWS (2010)
Efficacy of Imatinib in Aggressive Fibromatosis: Results of a Phase II Multicenter Sarcoma Alliance for Research through Collaboration (SARC) Trial
Rashmi Chugh et al.
CLINICAL CANCER RESEARCH (2010)
Lestaurtinib Enhances the Antitumor Efficacy of Chemotherapy in Murine Xenograft Models of Neuroblastoma
Radhika Iyer et al.
CLINICAL CANCER RESEARCH (2010)
Anti-Angiogenic Therapies for Children with Cancer
N. Andre et al.
CURRENT CANCER DRUG TARGETS (2010)
Lack of Efficacy of Bevacizumab Plus Irinotecan in Children With Recurrent Malignant Glioma and Diffuse Brainstem Glioma: A Pediatric Brain Tumor Consortium Study
Sridharan Gururangan et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Sorafenib Plus Valproic Acid for Infant Spinal Glioblastoma
Christopher Alan Rokes et al.
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY (2010)
Sunitinib Induces Apoptosis and Growth Arrest of Medulloblastoma Tumor Cells by Inhibiting STAT3 and AKT Signaling Pathways
Fan Yang et al.
MOLECULAR CANCER RESEARCH (2010)
Bevacizumab in recurrent high-grade pediatric gliomas
Ashwatha Narayana et al.
NEURO-ONCOLOGY (2010)
Tumour vasculature and angiogenic profile of paediatric pilocytic astrocytoma; is it much different from glioblastoma?
M. Sie et al.
NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY (2010)
Tumor Microvasculature and Microenvironment: Novel Insights Through Intravital Imaging in Pre-Clinical Models
Dai Fukumura et al.
MICROCIRCULATION (2010)
Multiple receptor tyrosine kinases regulate HIF-1α and HIF-2α in normoxia and hypoxia in neuroblastoma: implications for antiangiogenic mechanisms of multikinase inhibitors
M. B. Nilsson et al.
ONCOGENE (2010)
Retinoic Acid Enhances Sensitivity of Neuroblastoma Cells for Imatinib Mesylate
Ingo Neumann et al.
PEDIATRIC BLOOD & CANCER (2010)
Imatinib Mesylate for Children With Dermatofibrosarcoma Protuberans (DFSP)
Saskia L. M. Gooskens et al.
PEDIATRIC BLOOD & CANCER (2010)
Wilms' tumour protein Wt1 stimulates transcription of the gene encoding vascular endothelial cadherin
Karin M. Kirschner et al.
PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY (2010)
Why are tumour blood vessels abnormal and why is it important to know?
J. A. Nagy et al.
BRITISH JOURNAL OF CANCER (2009)
C-kit protein expression in Wilms' tumour: An immunohistochemical study
G. Giordano et al.
EJSO (2009)
Anti-endoglin monoclonal antibodies are effective for suppressing metastasis and the primary tumors by targeting tumor vasculature
Shima Uneda et al.
INTERNATIONAL JOURNAL OF CANCER (2009)
Metronomic scheduling of imatinib abrogates clonogenicity of neuroblastoma cells and enhances their susceptibility to selected chemotherapeutic drugs in vitro and in vivo
Ebba Paimberg et al.
INTERNATIONAL JOURNAL OF CANCER (2009)
Alveolar Rhabdomyosarcoma of the Extremity and Nodal Metastasis: Is the In-Transit Lymphatic System at Risk?
Arnold C. Paulino et al.
PEDIATRIC BLOOD & CANCER (2009)
Objective Response of Multiply Recurrent Low-Grade Gliomas to Bevacizumab and Irinotecan
Roger J. Packer et al.
PEDIATRIC BLOOD & CANCER (2009)
In Vivo Antitumor and Antimetastatic Activity of Sunitinib in Preclinical Neuroblastoma Mouse Model
Libo Zhang et al.
NEOPLASIA (2009)
Platelet-derived growth factor receptor as a prognostic marker and a therapeutic target for imatinib mesylate therapy in osteosarcoma
Tadahiko Kubo et al.
CANCER (2008)
Vascular endothelial growth factor (VEGF)-C - a potent risk factor in children diagnosed with stadium 4 neuroblastoma
Michal Nowicki et al.
FOLIA HISTOCHEMICA ET CYTOBIOLOGICA (2008)
PDGFR-A is a therapeutic target in alveolar rhabdomyosarcoma
E. Taniguchi et al.
ONCOGENE (2008)
Initial testing (stage 1) of sunitinib by the pediatric preclinical testing program
John M. Maris et al.
PEDIATRIC BLOOD & CANCER (2008)
Bevacizumab suppresses neuroblastoma progression in the setting of minimal disease
Thomas L. Sims et al.
SURGERY (2008)
Compassionate use of bevacizumab (Avastin®) in children and young adults with refractory or recurrent solid tumors
M. Benesch et al.
ANNALS OF ONCOLOGY (2008)
A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: A children's oncology group study
Mason Bond et al.
PEDIATRIC BLOOD & CANCER (2008)
Modes of resistance to anti-angiogenic therapy
Gabriele Bergers et al.
NATURE REVIEWS CANCER (2008)
Overexpression of PDGF-BB decreases colorectal and pancreatic cancer growth by increasing tumor pericyte content
Marya F. McCarty et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
Revacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy
Paxton V. Dickson et al.
CLINICAL CANCER RESEARCH (2007)
Imatinib mesylate potentiates topotecan antitumor activity in rhabdomyosarcoma preclinical models
Heather P. McDowell et al.
INTERNATIONAL JOURNAL OF CANCER (2007)
The significance of VEGF-C/VEGFR-2 interaction in the neovascularization and prognosis of nephroblastoma (Wilms' tumour)
M. Nowicki et al.
HISTOPATHOLOGY (2007)
Markers of angiogenesis and clinical features in patients with sarcoma
Steven DuBois et al.
CANCER (2007)
Vasculopathy and disordered angiogenesis in selected rheumatic diseases: rheumatoid arthritis and systemic sclerosis
Alisa E. Koch et al.
ARTHRITIS RESEARCH & THERAPY (2007)
The anti-VEGF antibody bevacizumab potently reduces the growth rate of high-risk neuroblastoma xenografts
Lova Segerstrom et al.
PEDIATRIC RESEARCH (2006)
The prognostic significance of angiogenesis and the effect of vascular endothelial growth factor on angiogenic process in Wilms' tumour
Yasemin Ozluk et al.
PATHOLOGY (2006)
Effect of STI-571 (imatinib mesylate) in combination with retinoic acid and γ-irradiation on viability of neuroblastoma cells
J Rössler et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2006)
Angiogenesis and Ewing sarcoma - relationship to pulmonary metastasis and survival
D Mikulic et al.
JOURNAL OF PEDIATRIC SURGERY (2006)
Imatinib mesylate: An attractive alternative in young children with large, surgically challenging dermatofibrosarcoma protuberans
VE Price et al.
PEDIATRIC BLOOD & CANCER (2005)
Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy
RK Jain
SCIENCE (2005)
Effect of imatinib mesylate on neuroblastoma tumorigenesis and vascular endothelial growth factor expression
K Beppu et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2004)
VEGF expression in osteosarcoma correlates with vascular permeability by dynamic MRI
BH Hoang et al.
CLINICAL ORTHOPAEDICS AND RELATED RESEARCH (2004)
Prognostic relevance of increased angiogenesis in osteosarcoma
M Kreuter et al.
CLINICAL CANCER RESEARCH (2004)
Determination of vascular endothelial growth factor (VEGF) overexpression in soft tissue sarcomas and the role of overexpression in leiomyosarcoma
A Potti et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2004)
Tumor angiogenesis and outcome in osteosarcoma
D Mikulic et al.
PEDIATRIC HEMATOLOGY AND ONCOLOGY (2004)
c-kit receptor expression in Ewing's sarcoma:: Lack of prognostic value but therapeutic targeting opportunities in appropriate conditions
K Scotlandi et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Increased microvascular density predicts relapse in Wilms' tumor
LP Abramson et al.
JOURNAL OF PEDIATRIC SURGERY (2003)
Expression and prognostic relevance of vascular endothelial growth factor (VEGF) and its receptor (FLT-1 in nephroblastoma
MA Ghanem et al.
JOURNAL OF CLINICAL PATHOLOGY (2003)
Lack of prognostic significance of intratumoral angiogenesis in nonmetastatic osteosarcoma
E Mantadakis et al.
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY (2001)
分享论文
